Prostate Cancer


The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.

Trial overview


Prostate cancer


A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapyand LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients.

Eligibility criteria

To be considered for the study you must meet the following criteria:

  • Aged 18+ Male
  • Histologically confirmed adenocarcinoma of the prostate
  • Previously treated with radical prostatectomy with or without lymph node dissection and any post-operative prostate-specific antigen (PSA) measurement of less than (<) 0.1 nanogram/millilitre (ng/mL) between Week 6 and Week 20
  • PSMA-PET-positive for at least one loco-regional (pelvic) lesion with or without distant (extra-pelvic) will be eligible to be randomized to either arm of the Interventional Cohort. PSMA-PET-negative for any prostate cancer lesions (that is no loco-regional lesion and no distant lesion) will be eligible for inclusion in the Observational Cohort
  • Biochemically recurrent prostate cancer after RP with a high risk of developing metastasis defined as pathological Gleason score greater than or equal to (>=) 8 evaluated from prostate tissue specimen at radical prostatectomy, OR PSADT less than or equal to (<=) 12 months at the time of screening
  • No evidence of prostate cancer metastases
  • Eastern Cooperative Oncology Group Performance Status Grade 0 or 1

Study details

Apalutamide is a non-steroidal androgen receptor (AR) antagonist being developed for the treatment of prostate cancer. This study aims to determine if addition of apalutamide to RT+ LHRHa improves PSMA-PET metastatic progression-free survival. Patients with PSMA-PET positive hormone sensitive prostate cancer will be randomised to receive apalutamide+RT+LHRHa or  RT+LHRHa alone.

Patient who are screened but are negative on PSMA-PET will be offered participation in an observational cohort.

Further information

For more information regarding this clinical trial click here.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.